FDA Adverse Event Injury Summary report: N

PARIETEX

MDR report key: 20183408 · Received September 10, 2024

Report

Report Number
9615742-2024-01294
Event Type
Injury
Date Received
September 10, 2024
Report Date
September 10, 2024
Manufacturer
SOFRADIM PRODUCTION SAS
Product Code
FTL
UDI-DI
10884521179844
PMA / PMN Number
K110663
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
MA, US
Reporter Occupation
003

Narratives

Additional Manufacturer Narrative · 0

H6 IME E2402: LABS ABNORMAL FOR CRP, UNABLE TO HAVE BOWEL MOTION MEDTRONIC SUBMITS THIS REPORT TO COMPLY WITH FDA REGULATIONS 21 CFR PARTS 4 AND 803. MEDTRONIC HAS MADE REASONABLE EFFORTS TO PROVIDE AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. MEDTRONIC WILL SUBMIT A SUPPLEMENTAL REPORT IF ADDITIONAL RELEVANT INFORMATION BECOMES KNOWN.

Description of Event or Problem · 0

THE PATIENT'S ATTORNEY ALLEGED A DEFICIENCY AGAINST THE DEVICE. THE PRODUCT WAS USED FOR THERAPEUTIC TREATMENT OF AN INCISIONAL HERNIA. IT WAS REPORTED THAT AFTER IMPLANT, THE PATIENT EXPERIENCED ATROPHIC LATERAL MUSCLES, FEVER, SEROMA, ANXIETY, LABS ABNORMAL FOR CRP, EMESIS, OPEN WOUND WITH BLEEDING, INFLAMMATION WITH SWELLING, HERNIA RECURRENCE, UNABLE TO HAVE BOWEL MOTION, DIAPHORETIC, ABDOMINAL PAIN, DISCOMFORT, & PAIN. POST-OPERATIVE PATIENT TREATMENT INCLUDED CT SCAN, ANTIBIOTICS, EPIDURAL PCA, IV/ORAL PAIN MEDICATION, IV FLUIDS, ANTIEMETICS, DIAZEPAM, WOUND CARE, PHYSIOTHERAPY, & HOSPITALIZATION.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
2330396 PARIETEX MESH, SURGICAL, POLYMERIC FTL SOFRADIM PRODUCTION SAS PCO3020FX PQD0717X 10884521179844

Patients

Seq Age Sex Outcome Treatment
1 NA Female Required Intervention| H